Paul Choppa joined Neogenomics in January of 2020 through the acquisition of the Oncology Division from Human Longevity Inc., La Jolla, California (US). Paul has a broad background in developing molecular based assays across multiple technology platforms with a primary focus in oncology. Along with leading assay development teams he also has considerable experience running clinical operations for some of the leading molecular oncology laboratories in the US. Over the past 20 years he has led assay development teams in support of both clinical operations and pharma services for Human Longevity, Thermo Fisher, Clarient/GE Health Care and IMPATH/Genzyme Genetics.
Division Vice President